Clinical Trial Update: A Study on the Effects of Ranolazine on Exercise Duration in Subjects With Chronic Stable Angina and Coronary Artery Disease (CAD) With Type 2 Diabetes Mellitus (T2DM) [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating the effects of ranolazine on exercise duration in patients with chronic stable angina and coronary artery disease with type 2 diabetes …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Angina Pectoris
• Coronary Artery Disease
• Type 2 Diabetes Mellitus

Drugs mentioned

• Ranexa (ranolazine)

Snippet

Sponsor: Gilead Sciences | Conditions: Angina Pectoris, Coronary Artery Disease | Phase 4 | Status: WITHDRAWN